The Amyloidosis Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The Amyloidosis Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company). The supporters have no influence over the production of the content.

Latest Videos The Amyloidosis Sessions Conferences Topics Features Podcasts

Welcome to The Amyloidosis Channel

Reporting from key international congresses and speaking with world-leading experts, VJHemOnc brings you the latest exciting advances in amyloidosis research, diagnosis and care. The Amyloidosis Channel delivers regular video interviews, roundtable discussions, podcasts and feature articles, so that you can keep up-to-date with all the practice-changing developments in amyloidosis.

Explore The Amyloidosis Channel to learn about the latest clinical trial updates, novel therapeutics and regimens, diagnostic advances and optimal management across all amyloidosis subtypes, including amyloid light chain (AL), amyloid A (AA), and transthyretin (ATTR) amyloidosis.

Conferences

ASH 2022
ISA 2022
IMS 2022
EHA 2022
COMy 20222
Myeloma 2022
0:44
Outcomes of patients with AL amyloidosis after failure of daratumumab-based therapy
Efstathios Kastritis • 11 Dec 2022
1:37
The importance of the multidisciplinary team in treating patients with myeloma and amyloidosis
Naresh Bumma • 11 Dec 2022
0:53
AQUARIUS: investigating the safety of D-VCd in patients with newly diagnosed AL amyloidosis
Efstathios Kastritis • 11 Dec 2022
1:04
EMN 27: Phase II study of belantamab mafodotin in patients with R/R AL amyloidosis
Efstathios Kastritis • 11 Dec 2022
View All Videos
4:18
Considerations for transplantation in AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
1:47
Current and emerging antibody-based immunotherapies in AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
2:38
Unmet needs in imaging for the diagnosis of AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
3:05
Sensitive detection of TTR aggregates for early diagnosis and monitoring of ATTR amyloidosis
Lorena Saelices • 7 Sep 2022
View All Videos
0:52
Differences in approaches to managing patients with multiple myeloma vs amyloidosis
Beth Faiman • 26 Aug 2022
1:53
ALTITUDE: venetoclax, daratumumab, and dexamethasone in systemic AL amyloidosis with t(11;14)
Sandy Wong • 26 Aug 2022
2:11
Using anti-myeloma agents in amyloidosis
Sandy Wong • 26 Aug 2022
1:44
Evaluating the impact of screening on survival in AL amyloidosis
Sandy Wong • 26 Aug 2022
View All Videos
1:00
Unmet needs in AL amyloidosis: treatment options for R/R patients
Jahanzaib Khwaja • 10 Jun 2022
0:48
Belantamab mafodotin in relapsed systemic AL amyloidosis
Jahanzaib Khwaja • 10 Jun 2022
2:11
Selecting patients with AL amyloidosis for autoHSCT
Iuliana Vaxman • 12 Jun 2022
0:57
The promise of CAR-T therapy for the treatment of AL amyloidosis
Carlos Fernández De Larrea • 10 Jun 2022
View All Videos
2:36
Looking forward to ISA 2022
Joan Bladé • 12 May 2022
2:18
The potential of CAR-T therapy for the treatment of amyloidosis
Giampaolo Merlini • 10 May 2022
5:57
Treatment approaches for amyloidosis patients with advanced cardiac involvement
Giampaolo Merlini • 10 May 2022
1:02
How the amyloidosis treatment landscape has transformed in recent years
Joan Bladé • 12 May 2022
View All Videos
1:44
Therapeutic approaches for AL amyloidosis
Angela Dispenzieri • 27 Mar 2022
2:38
The importance of early diagnosis in AL amyloidosis
Angela Dispenzieri • 27 Mar 2022
2:11
Unmet needs and challenges in amyloidosis
Angela Dispenzieri • 27 Mar 2022
3:01
Novel promising agents and clinical trials in amyloidosis
Angela Dispenzieri • 27 Mar 2022
View All Videos

Topics

MRD
Disease Biology
Trial Updates
Immuno-Oncology
Treatment
CAR-T therapy
2:13
Advances & unanswered questions about the role of MRD in AL amyloidosis
Andrew Staron • 5 Sep 2022
3:19
Impact of BM MRD status on the quality of organ response in AL amyloidosis
Rajshekhar Chakraborty • 7 Sep 2022
1:11
AL amyloidosis poster highlights from ISA
Paolo Milani • 7 Sep 2022
1:53
The prognostic role of MRD in AL amyloidosis
Andrew Staron • 5 Sep 2022
View All Videos
2:14
Selecting patients for autologous transplantation in AL amyloidosis: current practice & challenges
Ashutosh Wechalekar • 12 Dec 2022
1:51
The role of mass spectrometry in response assessment in patients with AL amyloidosis
Ashutosh Wechalekar • 12 Dec 2022
1:11
Evaluating the prognostic significance of CPCs in AL amyloidosis with next-generation flow cytometry
Efstathios Kastritis • 11 Dec 2022
1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz • 21 Nov 2022
View All Videos
1:26
Evaluating the efficacy of ixazomib, cyclophosphamide and dexamethasone in amyloidosis
Shaji Kumar • 11 May 2023
1:04
EMN 27: Phase II study of belantamab mafodotin in patients with R/R AL amyloidosis
Efstathios Kastritis • 11 Dec 2022
2:49
Highlights in AL amyloidosis from ASH 2022: EMN22, EMN27 & predictors of hematologic CR
Vaishali Sanchorawala • 12 Dec 2022
1:20
Phase II study investigating the efficacy of daratumumab in patients with stage 3B AL amyloidosis
Efstathios Kastritis • 11 Dec 2022
View All Videos
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
1:26
Evaluating the efficacy of ixazomib, cyclophosphamide and dexamethasone in amyloidosis
Shaji Kumar • 11 May 2023
0:44
Outcomes of patients with AL amyloidosis after failure of daratumumab-based therapy
Efstathios Kastritis • 11 Dec 2022
0:53
AQUARIUS: investigating the safety of D-VCd in patients with newly diagnosed AL amyloidosis
Efstathios Kastritis • 11 Dec 2022
View All Videos
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
1:18
Overview of the updated NCCN Clinical Practice Guidelines for systemic AL amyloidosis
Shaji Kumar • 11 May 2023
1:26
Evaluating the efficacy of ixazomib, cyclophosphamide and dexamethasone in amyloidosis
Shaji Kumar • 11 May 2023
0:44
Outcomes of patients with AL amyloidosis after failure of daratumumab-based therapy
Efstathios Kastritis • 11 Dec 2022
View All Videos
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
2:11
Using anti-myeloma agents in amyloidosis
Sandy Wong • 26 Aug 2022
2:12
IMS session highlights: clinical challenges in multiple myeloma
Tiffany Richards • 26 Aug 2022
5:57
Feasibility of BCMA-directed CAR-T therapy in R/R AL amyloidosis
Moshe Gatt • 5 Sep 2022
View All Videos

The Amyloidosis Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company).

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Amyloidosis Channel, please contact us

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals